BioCentury | Mar 2, 2018
Politics & Policy

Volume of comments delays Foundation coverage decision

...covers three other NGS genomic oncology panel tests that FDA has approved: Foundation's FoundationFocus CDxBRCA; Oncomine Dx Target Test...
...should be implemented in a way that does not add undue burden to patients. Erin McCallister FoundationFocus CDxBRCA FoundationOne Oncomine Dx Target Test Foundation...
BioCentury | Jan 4, 2018
Strategy

Next generation resolutions

...Clovis Oncology Inc. (NASDAQ:CLVS) June 2017 First NGS-based panel for multiple companion diagnostic indications Oncomine Dx Target Test...
BioCentury | Aug 18, 2017
Translation in Brief

Next-generation growth spurt

...to break new ground with regulators. In June, FDA approved Thermo Fisher Scientific Inc. (NYSE:TMO)'s Oncomine Dx Target Test...
...is not feasible. Variants with clinical claims were included in the validation studies for the Oncomine Dx Target Test...
BioCentury | Jul 21, 2017
Clinical News

FDA approves Novartis' NSCLC combo

...metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. FDA concurrently approved the Oncomine Dx Target Test...
...Tobacco Inc. Novartis AG Thermo Fisher Scientific Inc. BRAF MAP kinase kinase 1 (MAP2K1) (MEK1) MAP kinase kinase 2 (MAP2K2) (MEK2) Oncomine Dx Target Test...
BioCentury | Jul 21, 2017
Clinical News

FDA approves Novartis' NSCLC combo

...metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. FDA concurrently approved the Oncomine Dx Target Test...
...Tobacco Inc. Novartis AG Thermo Fisher Scientific Inc. BRAF MAP kinase kinase 1 (MAP2K1) (MEK1) MAP kinase kinase 2 (MAP2K2) (MEK2) Oncomine Dx Target Test...
Items per page:
1 - 5 of 5